Wagner F F, Kasulke D, Kerowgan M, Flegel W A
Abteilung Transfusionsmedizin, Universität Ulm, Germany.
Infusionsther Transfusionsmed. 1995 Oct;22(5):285-90. doi: 10.1159/000223144.
Current estimates of blood group frequencies in Germany were often derived from studies involving less than 12,000 individuals. The frequency of the D category VI was unknown.
ABO. Kell, and Rhesus blood group data of more than 600,000 donors were reviewed. Allele frequencies were derived by the maximum-likelihood method. The frequency of D category VI was determined in more than 70,000 Rhesus typings.
ABO allele frequencies were: O: 0.640, A: 0.279. B: 0.081. Rhesus haplotype frequencies were: cde: 0.394, CDe: 0.431, cDE: 0.136, cDe: 0.021, and Cde: 0.011. D category VI represented 7%, of all weak D (formerly D(u)). The 95% confidence interval for the D category VI frequency was 1:3,600-1:11,200. Kell allele frequencies were: K: 0.040, and k: 0.960, 95% confidence intervals for rare phenotypes were: Oh: 1:88,000-1:1,760,000, p: 1:200,000-1:5,200,000. Rh(null): 1:180,000-1:10,300,000, and D-deletion: 1: 180,000-0.
We presented refined estimates of ABO, Rhesus D and Kell blood group frequencies and established reliable frequency estimates for Rhesus haplotype and some rare blood groups. The prevalence of D category VI was about 0.02%, which necessitates specific detection for Rh-D-negative transfusion therapy. A protocol is presented for Rh D typing in transfusion recipients. which obviates the need for an antiglobulin test.
目前德国血型频率的估计值往往来自样本量不足12,000人的研究。D类别VI的频率尚不清楚。
回顾了60多万名献血者的ABO、凯尔(Kell)和恒河猴血型数据。等位基因频率通过最大似然法得出。在7万多次恒河猴血型检测中确定了D类别VI的频率。
ABO等位基因频率为:O:0.640,A:0.279,B:0.081。恒河猴单倍型频率为:cde:0.394,CDe:0.431,cDE:0.136,cDe:0.021,Cde:0.011。D类别VI占所有弱D(以前的D(u))的7%。D类别VI频率的95%置信区间为1:3,600 - 1:11,200。凯尔等位基因频率为:K:0.040,k:0.960,罕见血型的95%置信区间为:Oh:1:88,000 - 1:1,760,000,p:1:200,000 - 1:5,200,000,Rh(null):1:180,000 - 1:10,300,000,以及D缺失:1:180,000 - 0。
我们给出了ABO、恒河猴D和凯尔血型频率的精确估计,并为恒河猴单倍型和一些罕见血型建立了可靠的频率估计。D类别VI的患病率约为0.02%,这使得Rh - D阴性输血治疗需要进行特定检测。本文给出了输血受者Rh D血型分型的方案,该方案无需抗球蛋白试验。